News
CRBU
0.3619
-4.81%
-0.0183
Weekly Report: what happened at CRBU last week (1102-1106)?
Weekly Report · 5d ago
Caribou Biosciences reports Q3 EPS (25c), consensus (26c)
TipRanks · 11/05 22:35
Weekly Report: what happened at CRBU last week (1026-1030)?
Weekly Report · 11/02 09:53
Weekly Report: what happened at CRBU last week (1019-1023)?
Weekly Report · 10/26 09:53
Weekly Report: what happened at CRBU last week (1012-1016)?
Weekly Report · 10/19 09:53
Weekly Report: what happened at CRBU last week (1005-1009)?
Weekly Report · 10/12 09:57
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
Benzinga · 10/09 19:03
This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Benzinga · 10/09 14:37
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 10/08 17:05
Thursday Sector Laggards: Biotechnology, Packaging & Containers
NASDAQ · 10/08 16:01
This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Benzinga · 10/08 12:13
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Benzinga · 10/08 12:07
Caribou Biosciences Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 10/08 10:38
Caribou Biosciences moved to No Rating at BofA
TipRanks · 10/08 10:35
HC Wainwright & Co. Downgrades Caribou Biosciences to Neutral
Benzinga · 10/08 10:29
Caribou Biosciences downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 10/08 10:15
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 10/07 17:05
Caribou falls as analysts downgrade on plans to explore strategic alternatives
Seeking Alpha · 10/07 17:01
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
Benzinga · 10/07 16:02
This Option Care Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Benzinga · 10/07 15:52
More
Webull provides a variety of real-time CRBU stock news. You can receive the latest news about Caribou Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. The Company is dedicated to developing transformative therapies for patients with devastating diseases. The Company's chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Vispa-cel is an allogeneic anti-CD19 CAR-T cell therapy that has been evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy that is being evaluated in patients with relapsed or refractory multiple myeloma.